No Data
No Data
Shenzhen new industries biomedical engineering (300832.SZ) products have obtained IVDR CE certification.
Shenzhen New Industries Biomedical Engineering (300832.SZ) announced that recently, the company has released human immunodeficiency virus antigen and antibody detection reagents...
Guosen Securities: After the centralized procurement of IVD, the industry landscape has changed, and the assembly line has become a battleground.
In the environment of centralized procurement, having TLA products with low cost and high quality will become the core competitiveness of IVD companies.
Is Shenzhen New Industries Biomedical Engineering Co., Ltd. (SZSE:300832) Trading At A 24% Discount?
Shenzhen New Industries Biomedical Engineering (300832.SZ): The 'parathyroid hormone detection reagent kit (chemiluminescent magnetic microparticle method)' obtained the medical instruments registration certificate.
Gelonghui September 6th | Shenzhen New Industries Biomedical Engineering (300832.SZ) announced that recently, Shenzhen New Industries Biomedical Engineering Co., Ltd. received a "Medical Device Registration Certificate" issued by the Guangdong Provincial Administration of Pharmaceutical. For the parathyroid hormone assay kit (magnetic chemiluminescence method).
Shareholders Liu Haiyan and Xu Dinghong collectively reduced their holdings by 0.201 million shares in Shenzhen New Industries Biomedical Engineering (300832.SZ).
Shenzhen New Industries Biomedical Engineering (300832.SZ) announced that the company has received letters from Ms. Xu Dinghong, Ms. Liu Haiyan, and Ms. Zhang Lei...
Sinolink Securities: The large pharmaceutical sector is a key point in the mid-year report, and it is expected to see a overall recovery in the pharmaceutical sector in the second half of the year.
Looking ahead to the second half of the year, with the decline in the base, the recovery of procurement sentiment, and the stabilization of policy expectations, I am bullish on the recovery of demand for pharmaceutical and medical device products within hospitals, as well as the acceleration of performance growth. The pharmaceutical sector is expected to experience an overall reversal in the second half of the year.
No Data
No Data